Explore the research: spkl.io/6013ACDgN Presented today at #ECO2026 The SURMOUNT-MAINTAIN trial found that continuing tirzepatide at the maximum tolerated dose maintained bodyweight reduction and health-related benefits in adults with obesity
GLP-1 medications mimic the action of the GLP-1 hormone that is naturally released by the body and can help to reduce appetite, decrease overeating, and lose weight
Furthermore, PKA phosphorylates phosphatidylinositol-3-kinase (PI3K), subsequently resulting in the phosphorylation of protein kinase B (AKT), ultimately leading to the phosphorylation of Glycogen synthase kinase-3 (GSK-3)
This partial reversal may be driven by factors such as compliance challenges, waning drug efficacy or measurement limitations
There was also a positive result for the rate of nonfatal myocardial infarction events, which was lower for the albiglutide group (RR 0.75
As shown in Figure 3 , improvements in both parameters were already evident at T3 compared with baseline, with further improvements at T6 compared to T3
